Erik Tillman
Associate Director, Translational Biology and Pharmacology at Akero Therapeutics - South San Francisco, CA, US
Erik Tillman's Colleagues at Akero Therapeutics
Brittany De Temple
director of clinical operations and program management
Erik Tillman's Contact Details
HQ
650-487-6488
650-487-6488
Location
Cambridge,Massachusetts,United States
Cambridge,Massachusetts,United States
Company
Akero Therapeutics
Akero Therapeutics
Erik Tillman's Company Details
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH. Akero is headquartered in South San Francisco.
Frequently Asked Questions about Erik Tillman
Erik Tillman currently works for Akero Therapeutics.
Erik Tillman's role at Akero Therapeutics is Associate Director, Translational Biology and Pharmacology.
Erik Tillman's email address is ***@akerotx.com. To view Erik Tillman's full email address, please signup to ConnectPlex.
Erik Tillman works in the Research industry.
Erik Tillman's colleagues at Akero Therapeutics are Kitty Yale, Yasmine CPA, John CEP, William White, Whitney Withington, Brittany De Temple, Yuan Xu and others.
Erik Tillman's phone number is 650-487-6488